MENU
Showcases Stock ranks Forex

Bristol-Myers Squibb Company (BMY)
74.13  -0.4 (-0.54%) 08-16 16:00
Open: 74.36 Pre. Close: 74.53
High: 75.1 Low: 73.845
Volume: 9,026,976 Market Cap: 158,287M
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 75.245 - 75.672 75.672 - 76.136
Low: 72.644 - 73.121 73.121 - 73.638
Close: 73.233 - 74.06 74.06 - 74.958
Stock Technical Analysis
Overall:     
Target: Six months: 88.53
One year: 103.41
Support: Support1: 73.27
Support2: 71.71
Resistance: Resistance1: 75.80
Resistance2: 88.53
Pivot: 73.98
Moving Averages: MA(5): 74.71
MA(20): 73.75
MA(100): 75.43
MA(250): 67.75
MACD: MACD(12,26): -0.07
Signal(12,26,9): -0.29
%K %D: %K(14,3): 75.64
%D(3): 79.68
RSI: RSI(14): 49.06
52-Week: High: 80.59
Low: 53.22
Change(%): 8.2
Average Vol(K): 3-Month: 11519
10-Days: 7999
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ BMY ] has closed below upper band by 46.3%. Bollinger Bands are 18.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Tue, 16 Aug 2022
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics - Bristol-Myers Squibb

Mon, 15 Aug 2022
See Which Of The Latest 13F Filers Holds Bristol Myers Squibb - Nasdaq

Mon, 15 Aug 2022
Bristol-Myers Squibb Company – Consensus Indicates Potential 9.3% Upside - DirectorsTalk Interviews

Thu, 11 Aug 2022
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch

Wed, 10 Aug 2022
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma - Bristol-Myers Squibb

Mon, 08 Aug 2022
What’s Next For Bristol Myers Squibb Stock? - Forbes

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 2140.00
Shares Float (M) 2130.00
% Held by Insiders 0.07
% Held by Institutions 78.67
Shares Short (K) 27330
Shares Short Prior Month (K) 34460
Stock Financials
EPS 3.010
Book Value (p.s.) 15.270
Profit Margin 14.04
Operating Margin 22.42
Return on Assets (ttm) 6.3
Return on Equity (ttm) 19.1
Qtrly Rev. Growth 1.6
Gross Profit (p.s.) 17.313
Sales Per Share 22.028
EBITDA (p.s.) 9.874
Qtrly Earnings Growth 40.40
Operating Cash Flow (M) 15400.00
Levered Free Cash Flow (M) 13860.00
Stock Valuation
PE Ratio 24.63
PEG Ratio 2.00
Price to Book value 4.85
Price to Sales 3.37
Price to Cash Flow 10.30
Stock Dividends
Dividend 0.540
Dividend Yield 0.01
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android